Brand-Name Three-Way Comparison
Retatrutide vs Ozempic vs Wegovy: How They Compare in 2026
The retatrutide vs Ozempic vs Wegovy question is really a regulatory question first. Ozempic is FDA-approved for type 2 diabetes (2017). Wegovy is FDA-approved for obesity (2021) and cardiovascular risk reduction (2024). Retatrutide is investigational, with Phase 3 trials still running and no brand name yet. Two of the three are actually the same molecule (semaglutide) at different doses for different indications. The third is a triple-agonist that posted 24.2% weight loss in a Phase 2 trial but cannot be prescribed in 2026.
Key Takeaways
- Ozempic and Wegovy are the same molecule (semaglutide) at different doses for different FDA indications: 2.0 mg weekly for type 2 diabetes, and a recommended 2.4 mg weekly maintenance dose (7.2 mg maximum) for chronic weight management.
- Retatrutide is investigational. It is not FDA-approved, has no brand name, and is not available at pharmacies or through telehealth. In the US, lawful access is limited to a clinical trial or Lilly's expanded access program (ClinicalTrials.gov NCT07629401), which a doctor must request, for adults with a BMI of 35 or more whose obesity has not responded to the highest available dose of current weight-loss treatment, who have two or more serious obesity-related complications, and who cannot join a trial.
- Trial weight loss varies by indication and dose: Wegovy 2.4 mg produced 14.9% over 68 weeks (STEP 1). Retatrutide 12 mg produced 24.2% over 48 weeks in a Phase 2 trial. Ozempic at type 2 diabetes doses produces more modest weight loss because diabetes control, not weight, was the primary endpoint.
- Both semaglutide brands carry an FDA cardiovascular risk-reduction indication; retatrutide has none. Wegovy's covers adults with established cardiovascular disease and obesity or overweight (2024, based on the SELECT trial); Ozempic's covers adults with type 2 diabetes and established cardiovascular disease.
- Side effects are GI-dominant for all three. In retatrutide's Phase 3 TRIUMPH-1 trial (Jastreboff et al., NEJM 2026; adults without diabetes), nausea affected 28.6 to 42.4 percent across 4 to 12 mg versus 14.8 percent on placebo; the Wegovy label reports nausea in 44 percent on 2.4 mg versus 16 percent on placebo. These are separate trials, not a head-to-head comparison.
2017
Ozempic FDA approval (type 2 diabetes)
2021
Wegovy FDA approval (obesity)
Phase 3
Retatrutide trial status (no brand yet)
0
Head-to-head trials among the three
Retatrutide vs Ozempic vs Wegovy: Quick Comparison Table
This is the fastest way to see how the three line up on the dimensions people search for: molecule, FDA indication, approval year, maximum dose, headline trial weight loss, half-life, and how you actually get hold of each one.
| Feature | Ozempic | Wegovy | Retatrutide |
|---|---|---|---|
| Molecule | Semaglutide | Semaglutide | Retatrutide (LY3437943) |
| Mechanism | GLP-1 agonist (single) | GLP-1 agonist (single) | GLP-1/GIP/glucagon agonist (triple) |
| FDA Indication | Type 2 diabetes | Obesity + cardiovascular risk reduction | None (investigational) |
| Approval Year | 2017 | 2021 (obesity); 2024 (CV) | Phase 3 ongoing |
| Max Dose | 2.0 mg weekly | 2.4 mg weekly maintenance (7.2 mg max) | 12 mg weekly (trial) |
| Trial Weight Loss | ~5 to 7% at T2D doses | 14.9% (STEP 1, 68 wks) | 24.2% (Phase 2, 48 wks) |
| Half-Life | ~7 days | ~7 days | ~6 days |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
| Availability | Pharmacy, prescription | Pharmacy, prescription | US: clinical trial or Lilly's narrow expanded access program (NCT07629401) |
Retatrutide is investigational and not FDA-approved
In the US, the routes available today are clinical trial participation or Lilly's narrow expanded access program (NCT07629401). The 24.2% figure is from a Phase 2 trial, and Phase 3 results may differ. It cannot be prescribed, sold at a pharmacy, or offered through telehealth in 2026.
Retatrutide vs Ozempic vs Wegovy: FDA Status Is the Key Divide
Three medications, three regulatory positions. This is the dimension that decides whether the comparison is even practical for you in 2026.
Ozempic: FDA-Approved for Type 2 Diabetes (2017)
The FDA approved Ozempic on December 5, 2017 for adults with type 2 diabetes. The original maximum dose was 1.0 mg weekly; the FDA expanded that to 2.0 mg in 2022. Ozempic is not FDA-approved for chronic weight management. Off-label prescribing for weight loss happens but is not the labeled indication, and insurance coverage for off-label weight-loss use is often denied. Weight loss at type 2 diabetes doses tends to be more modest than what Wegovy produces at its higher obesity dose, because the primary trial endpoint for Ozempic was glycemic control, not weight.
Wegovy: FDA-Approved for Obesity (2021) and Cardiovascular Risk Reduction (2024)
The FDA approved Wegovy on June 4, 2021 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbidity. The recommended maintenance dose is 2.4 mg weekly, with a maximum of 7.2 mg weekly. Same molecule as Ozempic (semaglutide), same manufacturer (Novo Nordisk), different dose and different indication. In 2024 the FDA added a cardiovascular risk-reduction indication for Wegovy in adults with established cardiovascular disease and BMI of at least 27, based on the SELECT trial (Lincoff et al., NEJM 2023). That makes Wegovy the first weight-loss medication to carry a cardiovascular outcomes indication, and it is the single most important regulatory difference between Wegovy and Ozempic.
Retatrutide: Investigational, Phase 3 Ongoing
Retatrutide (molecule ID LY3437943) is in Phase 3 trials as of 2026, developed by Eli Lilly. It is a triple GLP-1/GIP/glucagon receptor agonist, the first of its class in late-stage development. It is not FDA-approved, has no brand name, and cannot be prescribed, sold at a pharmacy, or offered through telehealth. In the US, the routes available today are enrollment in a clinical trial via ClinicalTrials.gov and Lilly's narrow expanded access program (NCT07629401). Research-peptide sourcing is a separate channel with significant quality and legal risk and should not be confused with an investigational drug trial. For more, see the retatrutide clinical trials and compounded retatrutide articles.
Model Any of the Three on One Calculator
Use the free GLP3Planner pharmacokinetic calculators to map dose schedules and half-life decay for retatrutide or semaglutide (Ozempic and Wegovy).
Retatrutide vs Ozempic vs Wegovy: Weight Loss Trial Data
Read these as separate trial results, not a head-to-head ranking
The Phase 2 retatrutide trial, STEP 1 (Wegovy), and the Ozempic type 2 diabetes program enrolled different populations, ran for different durations, and measured different primary endpoints. A higher percentage in one trial does not prove one drug outperforms another in the same patient. No head-to-head trial exists between retatrutide and either semaglutide brand.
Retatrutide: 24.2% at 48 Weeks (Phase 2)
In the Phase 2 trial (Jastreboff et al., NEJM 2023), 338 adults with obesity received retatrutide at maintenance doses of 1, 4, 8, or 12 mg weekly. The 12 mg arm produced 24.2% mean body weight loss at 48 weeks. These are Phase 2 results, and the ongoing Phase 3 program may report different numbers when it completes.
Wegovy: 14.9% at 68 Weeks (STEP 1)
STEP 1 (Wilding et al., NEJM 2021) tested semaglutide 2.4 mg weekly in adults with overweight or obesity. Mean body weight loss was 14.9% at 68 weeks. This is the trial that anchors the Wegovy obesity indication. For the full STEP 1 deep dive, see semaglutide weight loss results.
Ozempic: Modest Weight Loss at Type 2 Diabetes Doses
Ozempic was studied for glycemic control, not weight management, and the maximum approved type 2 diabetes dose (2.0 mg) is below Wegovy's 2.4 mg obesity dose. Weight loss at Ozempic doses is real but more modest, typically in the 5 to 7 percent range in clinical use. Patients prescribed Ozempic for type 2 diabetes who want greater weight loss are sometimes transitioned to Wegovy by their prescriber. For the brand-by-brand comparison, see Ozempic vs Wegovy.
Why the Numbers Are Not Directly Comparable
Trial duration differences (48 versus 68 weeks), different participant populations, and different primary endpoints all affect the figures. Retatrutide's 24.2% is a Phase 2 result on a smaller cohort; Wegovy's 14.9% is a Phase 3 result on a larger one. Phase 3 retatrutide data, when it reports, may move the number in either direction.
Mechanism: Why Retatrutide's Trial Numbers Are Higher
Ozempic and Wegovy both contain semaglutide, a single-target GLP-1 receptor agonist. Activating GLP-1 suppresses appetite, slows gastric emptying so you feel full longer, and stimulates glucose-dependent insulin secretion. That single mechanism delivered 14.9% mean weight loss in STEP 1.
Retatrutide keeps the GLP-1 action and adds two more targets. The GIP receptor adds insulin-sensitivity and fat-storage modulation effects. The glucagon receptor adds energy expenditure and fat metabolism acceleration. Hitting three pathways at once is the mechanistic rationale behind the higher Phase 2 weight loss figure. The pharmacokinetic and discovery work behind the molecule was first detailed by Coskun et al. in Cell Metabolism (2022). For a deeper breakdown, see the GLP-3 vs GLP-1 comparison chart.
Side Effects: Retatrutide vs Ozempic vs Wegovy Compared
All three share a gastrointestinal-dominant side effect profile: nausea, diarrhea, vomiting, and constipation. Differences are in intensity, reported rates, and how well-characterized the long-term picture is.
| Side Effect Category | Ozempic and Wegovy (semaglutide) | Retatrutide (trial data) |
|---|---|---|
| GI events overall | Mild to moderate, dose-dependent | Mostly mild to moderate, dose-related (Phase 2) |
| Nausea, diarrhea, vomiting | Wegovy label, 2.4 mg: nausea 44%, diarrhea 30%, vomiting 24% (placebo 16%, 16%, 6%) | TRIUMPH-1 (Jastreboff et al., NEJM 2026), 12 mg, adults without diabetes: nausea 42.4%, diarrhea 32.0%, vomiting 25.3% (placebo 14.8%, 13.5%, 4.8%) |
| Long-term characterization | Best-characterized (longest market history) | Phase 2 plus Phase 3 results (TRIUMPH-1 in NEJM and TRIUMPH-2 in The Lancet, 2026); long-term safety still accumulating |
Sources: Wegovy prescribing information (Table 3) and TRIUMPH-1 (Jastreboff et al., NEJM 2026). The figures come from separate trials with different populations and durations, so they are not a head-to-head comparison. No trial has compared retatrutide directly with semaglutide.
An investigational drug cannot be called "safe"
Retatrutide's gastrointestinal adverse event rates matter because its long-term safety data is still being collected. Calling an investigational medication safe before its trial program completes is not appropriate. For the retatrutide side effect profile in detail, see the retatrutide side effects page.
Access and Cost: How You Actually Get Each One
This is the practical filter that decides which of the three is even an option for you in 2026.
Ozempic and Wegovy: Prescription, Telehealth, and Compounding
Both are available with a prescription, through pharmacies or telehealth providers. Insurance coverage differs: Ozempic is often covered for type 2 diabetes, while Wegovy coverage for weight management is frequently denied or requires prior authorization. Compounded semaglutide availability depends on FDA shortage status, and the policy landscape has shifted; for the current state of compounding, see the cost article below. Uninsured pricing direction: Wegovy is typically more expensive than Ozempic, reflecting the higher-dose obesity formulation.
Retatrutide: Clinical Trial or Expanded Access Only
Retatrutide cannot be prescribed, is not at any pharmacy, and is not offered through telehealth. In the US, the routes available today are enrollment in a retatrutide clinical trial or Lilly's narrow expanded access program (NCT07629401). Most retatrutide Phase 3 trials are no longer enrolling; check ClinicalTrials.gov for open studies; eligibility depends on the protocol. Cost questions do not yet apply because there is no commercial product. For where the timeline stands, see the retatrutide FDA approval timeline. For cost speculation once retatrutide does launch, see retatrutide cost and access.
Which One Is Right for You? A Decision Framework
Nothing here is a personalized recommendation. These are the questions a clinician would actually weigh with you. Use them to frame a conversation, not to self-prescribe.
1. Do you need treatment now?
If yes, only Ozempic and Wegovy qualify. Retatrutide is not an option outside an enrolled clinical trial or Lilly's expanded access program.
2. Do you have type 2 diabetes?
Ozempic is the labeled type 2 diabetes brand. Weight loss is a secondary benefit at type 2 diabetes doses.
3. Is weight management the primary goal?
Wegovy is the labeled obesity brand. Its 2.4 mg dose was tested specifically for chronic weight management.
4. Do you have established cardiovascular disease?
Wegovy carries an FDA-approved cardiovascular risk-reduction indication for adults with established cardiovascular disease and obesity or overweight (based on the SELECT trial). Ozempic's cardiovascular indication applies only to adults who also have type 2 diabetes. Retatrutide has none.
5. Interested in retatrutide?
Monitor ClinicalTrials.gov for open Phase 3 sites and discuss eligibility with your physician. There is no commercial pathway in 2026.
The Bottom Line
Ozempic and Wegovy are the same molecule, semaglutide, sold under different brand names at different maximum doses for different FDA indications. Ozempic is for type 2 diabetes; Wegovy is for obesity and, since 2024, cardiovascular risk reduction. Both can be prescribed today.
Retatrutide is an investigational triple agonist that outperformed both in Phase 2 weight loss data (24.2%), but it is not FDA-approved, has no brand name, and in the US is available today only through clinical trial enrollment or Lilly's narrow expanded access program (NCT07629401). The right choice between the two approved brands depends on your indication, insurance coverage, and what your prescriber thinks fits. Retatrutide remains a watch-this-space option, not a current one.
Video: A Naturopathic Doctor Compares the Three Brands
Dr. Brian Yeung, ND, walks through this same brand-name comparison (Retatrutide vs Wegovy vs Mounjaro), covering clinical trial data and how each medication positions in the weight-management landscape.
Frequently Asked Questions
Is retatrutide better than Wegovy?
In Phase 2 trials, retatrutide produced 24.2% body weight loss versus Wegovy's 14.9% in STEP 1. The figures come from different trials with different designs and populations, so they are not a direct head-to-head ranking. Retatrutide is also investigational and unavailable outside clinical trials, while Wegovy can be prescribed now. "Better" depends on access, approval status, and individual medical history.
Can I switch from Wegovy to retatrutide?
Not in 2026. Retatrutide is investigational, and in the US the routes available today are a clinical trial or Lilly's narrow expanded access program (NCT07629401), so it cannot be prescribed as a routine switch. If you are currently on Wegovy and interested in retatrutide, discuss trial eligibility with your physician. Most retatrutide Phase 3 trials are no longer enrolling; check ClinicalTrials.gov for open studies.
What is the strongest GLP-1 drug for weight loss?
Among approved medications, Wegovy (semaglutide 2.4 mg) produced 14.9% mean weight loss in STEP 1. Among investigational drugs, retatrutide showed 24.2% in Phase 2. "Strongest" cannot be determined without a head-to-head trial, and retatrutide is not yet approved or available outside trials.
What are the risks of retatrutide compared to Ozempic?
Both share GI side effects: nausea, diarrhea, vomiting, and constipation. In retatrutide's TRIUMPH-1 trial (Jastreboff et al., NEJM 2026; adults with obesity or overweight, without diabetes), nausea affected 28.6 to 42.4 percent across 4 to 12 mg versus 14.8 percent on placebo, and 4.1 to 11.2 percent stopped because of adverse events versus 4.6 percent on placebo. The Wegovy label reports nausea in 44 percent on semaglutide 2.4 mg versus 16 percent on placebo. These are separate trials with different populations and durations, not a head-to-head comparison. Semaglutide (Ozempic) has a better-characterized safety profile given its longer market history, while retatrutide's long-term safety data is still accumulating.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide, the same molecule from the same manufacturer (Novo Nordisk). The difference is regulatory and dose-based. Ozempic is FDA-approved for type 2 diabetes at up to 2.0 mg weekly. Wegovy is FDA-approved for chronic weight management at up to 2.4 mg weekly. Weight loss at Wegovy's higher dose is substantially greater than at Ozempic's diabetes doses.
Why are people stopping Wegovy?
Common reasons include cost (insurance often does not cover it for weight management), GI side effects at higher doses, and concerns about weight regain after stopping. These apply to semaglutide generally, not Wegovy specifically. Physician-supervised titration helps manage side effects, and stopping without guidance can lead to rapid weight regain.
What is the worst day on Wegovy?
Side effects typically peak in the first 1 to 2 weeks after each dose escalation step, easing over weeks 3 to 4. The highest-side-effect period is usually after escalating to the 1.0 mg or 1.7 mg dose steps, not at the maintenance dose. Slow titration and dietary adjustments help.
Is retatrutide FDA-approved?
No. As of 2026, retatrutide remains investigational with Phase 3 clinical trials ongoing. It is not FDA-approved for any indication, cannot be prescribed, and is not commercially available. In the US, the routes available today are enrollment in a clinical trial and Lilly's narrow expanded access program (NCT07629401).
What does Ozempic treat versus what does Wegovy treat?
Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management (obesity, or overweight with at least one weight-related comorbidity) and, since 2024, for reducing cardiovascular risk in adults with established cardiovascular disease and BMI of at least 27. Physicians sometimes prescribe Ozempic off-label for weight loss, but the approved indication is diabetes.
When will retatrutide be available like Ozempic and Wegovy?
Phase 3 results have been reported, and Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. FDA approval and commercial launch could follow, but no confirmed approval date exists. Monitor the retatrutide FDA approval timeline for updates.
Plan Your Schedule on Any of These Molecules
Join 675+ users modeling retatrutide and semaglutide (Ozempic and Wegovy) pharmacokinetics with the free GLP3Planner calculators.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. DOI: 10.1056/NEJMoa2307563.
- U.S. Food and Drug Administration. FDA Approves New Drug to Treat Type 2 Diabetes (Ozempic). FDA News Release. December 5, 2017.
- U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management in Adults (Wegovy). FDA News Release. June 4, 2021.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. DOI: 10.1016/j.cmet.2022.07.013.
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026. DOI: 10.1056/NEJMoa2604169.
- Eli Lilly Medical Information. What are the results of retatrutide from TRIUMPH-1 in participants with obesity or overweight without type 2 diabetes? (TRIUMPH-1 adverse-event table, citing the NEJM paper).
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. Published online September 29, 2026. DOI: 10.1016/S0140-6736(26)01861-1.
- WEGOVY (semaglutide) prescribing information, Section 6.1, Table 3. Novo Nordisk; DailyMed.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual results vary, and what works for one person may not be appropriate for another. Retatrutide is investigational and is not FDA-approved; the data described here are from clinical trials only and should not be used for self-treatment.
Related Articles
Retatrutide vs Tirzepatide vs Semaglutide: 2026 Comparison
The compound-level three-way comparison with mechanism, trial data, and SURMOUNT-5 head-to-head context.
Ozempic vs Wegovy: Same Molecule, Different Doses
The brand-by-brand semaglutide breakdown: indications, dosing, weight loss, insurance coverage, and cost.
Retatrutide Clinical Trials: Phase 3 Enrollment
Where the trial program stands, who is eligible, and how to check ClinicalTrials.gov for open studies.
GLP-3 vs GLP-1: Triple vs Single Agonist Comparison Chart
A receptor-class view of why each added target tracked with more weight loss in trials.